BCAB BioAtla
- 1.670
- +0.110+7.05%
BioAtla News
Buy Rating Affirmed for BioAtla on Strong Clinical Data and Robust Financials
LIDR, HOOK and BCAB Among Mid-day Movers
BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
BioAtla, Inc. (Nasdaq: BCAB),today announced expanded data at an upcoming presentation entitled, "Phase 1 study of evalstotug (BA3071), an anti-CTLA-4 Conditionally Active Biologic, in combination with nivolumab in advanced solid tumors", demonstrating confirmed responses with a potentially differentiated tolerability profile with the Company's novel, conditionally active anti-CTLA-4 agent, evalstotug, in combination with anti-PD-1 therapy.
BioAtla Is Maintained at Market Outperform by JMP Securities
BioAtla Is Maintained at Market Outperform by JMP Securities
BioAtla Price Target Cut to $5.00/Share From $12.00 by JMP Securities
BioAtla Price Target Cut to $5.00/Share From $12.00 by JMP Securities
Institutional Owners May Consider Drastic Measures as BioAtla, Inc.'s (NASDAQ:BCAB) Recent US$35m Drop Adds to Long-term Losses
JMP Securities Maintains BioAtla(BCAB.US) With Buy Rating, Cuts Target Price to $5
JMP Securities analyst Reni Benjamin maintains $BioAtla(BCAB.US)$ with a buy rating, and adjusts the target price from $12 to $5.According to TipRanks data, the analyst has a success rate of 35.5% and
Buy Rating for BioAtla: Promising Clinical Data and Strong Financial Position Signal Upside Potential
BioAtla Shares Are Trading Higher After the Company Reported Better-than-expected Q1 GAAP EPS Results.
BioAtla Shares Are Trading Higher After the Company Reported Better-than-expected Q1 GAAP EPS Results.
Express News | HC Wainwright & Co. Reiterates Buy on BioAtla, Maintains $7 Price Target
BioAtla Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/15/2024 137.29% HC Wainwright & Co. → $7 Reiterates Buy → Buy 03/28/2024 306.78% JMP Securities → $12 R
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Wednesday Ahead of Key Inflation, Retail Data
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.1% and the actively traded Invesco QQQ Trust (QQQ) edged up 0.04% in Wednesday's premarket activity, ahead of key inflation
Buy Rating Affirmed for BioAtla on Strong Clinical Data and Strategic Pipeline Progress
Earnings Call Summary | BioAtla(BCAB.US) Q1 2024 Earnings Conference
The following is a summary of the BioAtla, Inc. (BCAB) Q1 2024 Earnings Call Transcript:Financial Performance:BioAtla reported R&D expenses of $18.9 million for Q1 2024, down from $21.7 million in Q1
BioAtla Shares Jump 10% in Premarket Activity Wednesday as Diluted Net Loss Narrows in Q1
06:22 AM EDT, 05/15/2024 (MT Newswires) -- BioAtla Shares Jump 10% in Premarket Activity Wednesday as Diluted Net Loss Narrows in Q1 Price: 2.8800, Change: +0.27, Percent Change: +10.34
BioAtla, Inc. (BCAB) Q1 2024 Earnings Call Transcript
BioAtla, Inc. (BCAB) Q1 2024 Earnings Call Transcript
Express News | BioAtla Shares Are Trading Higher After the Company Reported Better-than-expected Q1 GAAP EPS Results
BioAtla | 10-Q: Quarterly report
12 Health Care Stocks Moving In Tuesday's After-Market Session
GainersArcutis Biotherapeutics (NASDAQ:ARQT) stock moved upwards by 16.4% to $9.46 during Tuesday's after-market session. The company's market cap stands at $1.0 billion. As per the press release, Q1
Express News | Bioatla Inc: Expect Operating Cash Burn to Be Approximately $20 Mln for Quarter Ending June 30, 2024
Analysis
Price Target
No Data
